2020 New Antibacterial Discovery and Development GRC/GRS

2020 新抗菌药物发现与开发 GRC/GRS

• 批准号: 9913855
• 负责人: Ruben Tommasi
• 金额: $ 0.65万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-05 至 2023-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9913855
• 关键词: Academia; Address; Adjuvant; Anti-Bacterial Agents; Antibiotic Resistance; Antibiotics; Area; Bacterial Infections; Basic Science; Biological; Biotechnology; Cells; Charge; Chemicals; Clinic; Clinical; Clinical Pathways; Clinical Trials Design; Collaborations; Communities; Community Networks; Companions; Critical Thinking; Data; Development; Diagnosis; Drug Industry; Drug resistance; ESKAPE pathogens; Environment; Failure; Fostering; Foundations; Future; Generations; Government; Government Agencies; Gram-Negative Bacteria; Human; Immune; Industry; Infection; Leadership; Learning; Medical; Medicine; Membrane; Modeling; National Institute of Allergy and Infectious Disease; Organism; Organizational Change; Outcome; Participant; Patients; Pharmaceutical Preparations; Program Development; Research; Research Personnel; Risk-Taking; Scientist; Talents; Therapeutic; Time; Translational Research; Validation; antimicrobial drug; career; clinical candidate; clinical development; drug development; drug discovery; drug resistant bacteria; experience; innovation; interdisciplinary approach; interest; lead optimization; meetings; next generation; novel; novel strategies; programs; research facility; success; support network; symposium

Summary The 2020 Gordon Research Conference on New Antibacterial Discovery and Development and the companion Gordon Research Seminar will bring highly experienced leaders in antibacterial drug discovery and development together with young investigators and those new to the field of antibiotics research in order to enable the next generation of safe and effective drugs. Discussion leaders and speakers are chosen from academia, industry, and government agencies to emphasize the breadth of talent and leadership necessary to drive innovation around target discovery and validation, hit identification and chemical optimization, and clinical trial design and execution. Previous meetings have defined the problem of antibiotic resistance, the challenges in antibiotic discovery and development faced over the past two decades, and the need for new pathways for clinical development. Those meetings have successfully created a community of idea generation and collaboration in what is otherwise a highly competitive scientific arena. This meeting will build on those foundations by exploring 1) Communicate novel approaches towards target selection and identification of cell active compounds, 2) Communicate key learnings from recent clinical development programs, and 3) Communicate and discuss novel, non-traditional approaches to antibacterial discovery and development in the next decade. Many strategic and organizational changes have taken place in the biotech and pharmaceutical industry over the last few years as well as a shift in emphasis at academic and government research facilities from early basic science to translational research. Because of the ever-changing environment, there has never been a more critical time for fostering a community of intellectuals dedicated to innovation and calculated risk-taking. This GRC/GRS will enable critical thinking, robust discussions around data gathering and interpretation, and learning from each other's challenges and successes. Most importantly the GRC/GRS meeting will provide a community and support network for scientists who have dedicated their careers to one of the most difficult and essential areas of human medicine.

摘要 2020年戈登抗菌新发现与开发研究会议 伙伴戈登研究研讨会将带来抗菌药物发现方面经验丰富的领导者 与年轻的研究人员和抗生素研究领域的新手共同努力和发展 以使下一代药物安全有效。讨论负责人和演讲者选自 学术界、工业界和政府机构强调以下方面所需的才华和领导力 围绕目标发现和验证、命中识别和化学优化推动创新，以及 临床试验设计和实施。以前的会议已经定义了抗生素耐药性的问题， 过去二十年来抗生素发现和开发面临的挑战，以及对新的 临床发展的路径。这些会议成功地创造了一个创意产生的社区 以及在竞争激烈的科学舞台上的合作。本次会议将建立在这些基础上 通过探索1)交流目标选择和细胞鉴定的新方法来奠定基础 活性化合物，2)交流从最近的临床开发计划中学到的关键知识，以及3) 交流和讨论新的、非传统的抗菌药发现和开发方法 下一个十年。 多年来，生物技术和制药行业发生了许多战略和组织上的变化。 过去几年，学术和政府研究机构的重点从早期的 从基础科学到转化性研究。由于环境的不断变化，从来没有出现过 现在是培养一群致力于创新和精打细算的冒险精神的知识分子的关键时刻。 GRC/GRS将促进批判性思维，围绕数据收集和解释展开强有力的讨论，以及 从彼此的挑战和成功中学习。最重要的是，GRC/GRS会议将提供 为把自己的职业生涯奉献给最困难和最困难的 人类医学的基本领域。